Twenty-two patients had tumors with evaluable PD-L1 expression; the majority (73%) were low expressors (vCPS <5%)....The mPFS is 11.3 mo in the overall ITT population and 10.7 mo in patients with low tumor PD-L1 expression. The mOS is 19.5 mo in the overall ITT population and 18.7 mo in the patients with low tumor PD-L1 expression….At 2-years of follow-up, 1L treatment of advanced GEA patients with DKN-01 in combination with tislelizumab and CAPOX resulted in a prolongation of PFS and OS compared with the modern SOC regimen of nivolumab plus chemotherapy, both in the overall population (mPFS 11.3 vs 7.7 mo; mOS 19.5 vs 13.8 mo) and in the PD-L1 low subgroup (mPFS 10.7 vs 7.5 mo; mOS 18.7 vs 12.4 mo), alongside a manageable safety profile....The prolonged PFS and OS observed in the current study are notable, especially in our trial population dominated by patients with tumors of low PD-L1 expression, where the known benefit of anti-PD-1 therapy is limited.